Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Pharmacol. Sep 16, 2026; 15(2): 115880
Published online Sep 16, 2026. doi: 10.5497/wjp.115880
Published online Sep 16, 2026. doi: 10.5497/wjp.115880
Re-evaluating aspirin in the era of potent P2Y12 inhibitors: Ticagrelor monotherapy after percutaneous coronary intervention
Abdul Basit, Muhammad Moneeb Anwar, Qamar Ismail, Abdullah Iftikhar, Department of Phar
Muhammad Hamza Aslam, Department of Pharmacology, Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College Lahore, Lahore 54000, Punjab, Pakistan
Muhammad Ahmad Sarwar, Department of Pharmacology, Pakistan Kidney and Liver Institute and Research Center, Lahore 54000, Punjab, Pakistan
Ammara Akram, Department of Pharmacology, Poonch Medical College, Rawalakot 12350, Pakistan
Majeed Haq, Department of Pharmacology, Shaheed Suhrawardy Medical College and Hospital, Dhaka 1207, Bangladesh
Author contributions: Basit A gave study conception and participated in manuscript revision and proofreading; Basit A, Aslam MH, Anwar MM, Sarwar MA, Akram A, Ismail Q, Iftikhar A, and Haq M analyzed the data, wrote the manuscript; Aslam MH, Anwar MM, Sarwar MA, and Akram A reviewed the manuscript thoroughly; Ismail Q, Iftikhar A, and Haq M did data extraction.
AI contribution statement: AI tools (Grammarly) were used solely for linguistic refinement and formatting assistance. No AI tool was involved in the generation of research data, interpretation of results, or formulation of conclusions. All AI-generated outputs were critically reviewed and revised by the authors.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Majeed Haq, Department of Pharmacology, Shaheed Suhrawardy Medical College and Hospital, Sher-E-Bangla Nagar, Dhaka 1207, Bangladesh.
Received: October 29, 2025
Revised: February 2, 2026
Accepted: February 25, 2026
Published online: September 16, 2026
Processing time: 318 Days and 15.4 Hours
Revised: February 2, 2026
Accepted: February 25, 2026
Published online: September 16, 2026
Processing time: 318 Days and 15.4 Hours
Core Tip
Core Tip: Ticagrelor monotherapy after short-term dual antiplatelet therapy significantly reduces bleeding without increasing ischemic risk in high-risk percutaneous coronary intervention patients. This meta-analysis of > 20000 patients supports aspirin discontinuation after 1-3 months of dual antiplatelet therapy. Findings reinforce evolving guidelines toward simplified, safer antiplatelet strategies post-percutaneous coronary intervention.